Merck Pays $2.75bn To Access VelosBio’s ROR1-Targeting ADCs
Private Biotech Raised $137m In Venture Capital In July
Executive Summary
Merck continues its cancer deal streak, purchasing a pipeline of antibody-drug conjugates and bispecific antibodies against receptor tyrosine kinase-like orphan receptor 1 (ROR1).
You may also be interested in...
Ipsen Dives Back Into Dealmaking With First ADC Pact
The French drugmaker has teamed up with South San Francisco's Sutro Biophgarma to bag the rights to a preclinical-stage ADC targeting ROR1.
Merck & Co. CEO Davis Debuts With A Leaner Organization And Money To Spend
Merck's new CEO Robert Davis talked about his vision for business development and how the company might use the $9bn gained from the spinout of Organon.
BMS, Eisai Team Up To Accelerate Development Of Solid-Tumor ADC
The US firm gets development and co-commercial rights to MORAb-202 for $650m up front. BMS joins AstraZeneca, Merck & Co. and Gilead in recent ADC deal-making.